Publications by authors named "Shivani Bhandarkar"
mRNA therapeutics offer a potentially universal strategy for the efficient development and delivery of therapeutic proteins. Current mRNA vaccines include chemically modified nucleotides to reduce cellular immunogenicity. Here, we develop an efficient, high-throughput method to measure human translation initiation on therapeutically modified as well as endogenous RNAs.
View Article and Find Full Text PDFArticle Synopsis
- Translation initiation significantly influences gene expression in eukaryotes, with eukaryotic initiation factor 3 (eIF3) playing a key role in recruiting ribosomes.
- This study examined how eIF3's binding to specific 5'-untranslated regions (5'-UTRs) of mRNAs leads to varying protein outputs, finding that it binds to a specific motif, AMAYAA, in some 5'-UTRs.
- The study demonstrates that mRNAs bound by eIF3 have higher ribosome density and are preferentially translated during stress, highlighting eIF3's role as a novel translational enhancer.
Article Synopsis
- Scientists are working on a new way to use mRNA to create medicines and vaccines that help our bodies make proteins better.
- They found that tiny pieces of RNA, just a few letters long, can really change how well this process works.
- A special type of RNA called N1-methylpseudouridine can help boost the effectiveness of these medicines even more than some current mRNA vaccines.